Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
BUSINESS
US FDA Accepts Relugolix for Review in Advanced Prostate Cancer
Myovant Sciences, a subsidiary of Sumitomo Dainippon Pharma, said on June 22 that the US FDA has accepted for review its new drug application (NDA) for relugolix for the treatment of men with advanced prostate cancer. The drug has been…
To read the full story
Related Article
- US Approves Myovant’s Relugolix Combo for Uterine Fibroids
May 28, 2021
- US FDA Accepts Myovant’s Relugolix Triple Combo for Review in Uterine Fibroids
August 19, 2020
- Relugolix Combo Filed in US for Uterine Fibroids
June 3, 2020
- Myovant Files Relugolix for Advanced Prostate Cancer in US
April 23, 2020
BUSINESS
- Maruho Secures South Korean Rights to Incyte’s Ruxolitinib Cream
October 21, 2026
- CMIC Turns to AI to Hear Job Applicants in Their Own Words
October 21, 2026
- Arthur D. Little Urges Pricing Revamp to Spur Regenerative Medicine in Japan
October 21, 2026
- Entyvio PIV Trial Links Disease Clearance to 70% Lower UC Complication Risk
October 21, 2026
- Toho Subsidiary Suffers Data Breach, HCP Info Exposed
October 20, 2026
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…